← Back to Screener
BeOne Medicines Ltd. American Depositary Shares (ONC)
Price$270.10
Value ScoreD
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-30.28%
Price vs S&P 500 (4W)-15.98%
VGM Score53.74
Market Capitalization$31.87B
P/E Ratio (Annual)148.17x
All Metrics
P/CF (Annual)15.78x
Book Value / Share (Quarterly)$3.13
P/TBV (Annual)9.04x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)58.68%
Cash Flow / Share (Quarterly)$1.25
Payout Ratio (TTM)11.01%
Price vs S&P 500 (YTD)-24.12%
Gross Margin (TTM)87.96%
Net Profit Margin (TTM)7.77%
EPS (TTM)$0.30
10-Day Avg Trading Volume4.13M
EPS Excl Extra (TTM)$0.30
Revenue Growth (5Y)78.32%
EPS (Annual)$0.14
Dividend / Share (Annual)$0.04
ROI (Annual)3.81%
Gross Margin (Annual)87.43%
Net Profit Margin (5Y Avg)-64.81%
Cash / Share (Quarterly)$3.27
P/E Basic Excl Extra (TTM)68.43x
Revenue Growth QoQ (YoY)31.02%
P/E Normalized (Annual)148.17x
ROA (Last FY)2.55%
Revenue Growth TTM (YoY)36.18%
EBITD / Share (TTM)$0.41
ROE (5Y Avg)-22.39%
Operating Margin (TTM)10.47%
Cash Flow / Share (Annual)$1.25
P/B Ratio7.06x
P/B Ratio (Quarterly)8.68x
Net Income / Employee (Annual)$18,184
EV / Revenue (TTM)5.47x
Net Interest Coverage (TTM)-132.16x
ROA (TTM)2.95%
EV / EBITDA (TTM)80.36x
EPS Incl Extra (Annual)$0.14
Current Ratio (Annual)3.47x
Quick Ratio (Quarterly)3.06x
3-Month Avg Trading Volume3.43M
52-Week Price Return20.61%
EV / Free Cash Flow (Annual)17.02x
P/E Incl Extra (TTM)68.43x
Revenue / Employee (TTM)$507,051
Tangible BV / Share (Quarterly)$3.00
P/S Ratio (Annual)5.66x
Asset Turnover (Annual)0.67x
52-Week High$346.00
Operating Margin (5Y Avg)-65.13%
EPS Excl Extra (Annual)$0.14
CapEx CAGR (5Y)7.69%
26-Week Price Return-22.36%
Quick Ratio (Annual)3.06x
13-Week Price Return-6.30%
Total Debt / Equity (Annual)0.25x
Current Ratio (Quarterly)3.47x
Enterprise Value$30.77B
Revenue / Share Growth (5Y)74.43%
Asset Turnover (TTM)0.77x
Revenue / Employee (Annual)$475,969
Inventory Turnover (Annual)1.22x
Pretax Margin (Annual)6.79%
Cash / Share (Annual)$3.27
3-Month Return Std Dev48.53%
Gross Margin (5Y Avg)84.47%
Net Income / Employee (TTM)$39,387
EBITDA Interim CAGR (5Y)36.09%
ROE (Last FY)4.77%
Net Interest Coverage (Annual)-8.59x
EPS Basic Excl Extra (Annual)$0.14
P/FCF (TTM)15.56x
Receivables Turnover (TTM)7.05x
EV / Free Cash Flow (TTM)15.02x
Total Debt / Equity (Quarterly)0.25x
EPS Incl Extra (TTM)$0.30
Receivables Turnover (Annual)7.05x
ROI (TTM)4.07%
P/S Ratio (TTM)5.32x
Pretax Margin (5Y Avg)-62.15%
Revenue / Share (Annual)$3.78
Tangible BV / Share (Annual)$3.00
Forward P/E64.47x
Price vs S&P 500 (52W)22.40%
P/E Ratio (TTM)68.43x
Year-to-Date Return-18.03%
5-Day Price Return-6.15%
EPS Normalized (Annual)$0.14
ROA (5Y Avg)-14.78%
Net Profit Margin (Annual)3.82%
Month-to-Date Return-9.73%
EBITD / Share (Annual)$0.31
Operating Margin (Annual)6.80%
LT Debt / Equity (Annual)0.22x
P/CF (TTM)14.18x
ROI (5Y Avg)-18.89%
P/E Excl Extra (TTM)68.43x
LT Debt / Equity (Quarterly)0.22x
EPS Basic Excl Extra (TTM)$0.30
P/TBV (Quarterly)9.04x
Payout Ratio (Annual)24.02%
P/B Ratio (Annual)8.68x
Dividend / Share (TTM)$0.04
Inventory Turnover (TTM)1.24x
Pretax Margin (TTM)10.46%
Book Value / Share (Annual)$3.13
Price vs S&P 500 (13W)-14.56%
Dividend Yield (TTM)0.16%
Beta0.75x
P/FCF (Annual)17.63x
Revenue / Share (TTM)$3.95
ROE (TTM)5.22%
52-Week Low$213.33
vGradeD
gGradeB
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ONCBeOne Medicines Ltd. American Depositary Shares | D | B | C | $270.10 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BeOne Medicines is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes targeted cancer treatments. The company's portfolio includes BRUKINSA (a Bruton's tyrosine kinase inhibitor), sonrotoclax (a BCL2 inhibitor), and other proprietary therapeutics. BeOne generates revenue primarily from the sale of its biopharmaceutical products across multiple oncology indications.